Health
Therapy
Cancer Prevention
Heron Therapeutics
$23.789876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$23.78
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.86 (-3.49%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell HRTX and other stocks, options, ETFs, and crypto commission-free!
About
Heron Therapeutics, Inc. Common Stock, also called Heron Therapeutics, is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. Read More The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
Employees
198
Headquarters
San Diego, California
Founded
1983
Market Cap
1.86B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.05M
High Today
$24.87
Low Today
$23.74
Open Price
$24.52
Volume
586.36K
52 Week High
$42.90
52 Week Low
$21.25
Collections
Health
Therapy
Cancer Prevention
Pharmaceutical
Biotechnology
Medical
Technology
News
MarketBeatMar 7
Stock Price, News, & Analysis for Heron Therapeutics
Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associat...
Yahoo FinanceFeb 22
Heron Therapeutics: 4Q Earnings Snapshot
SAN DIEGO (AP) _ Heron Therapeutics Inc. (HRTX) on Friday reported a loss of $49.6 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 63 cents. The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 46 cents per share. The pharmaceutical company posted revenue of $28.8 million in the period, surpassing Street forecasts. Four analysts surveyed by Zacks expected $28.1...
Price Paid on Robinhood
13% Lower
Right Now
52 Week Low
$21.25
Average Price Paid
$27.48
52 Week High
$42.90
Earnings
-$1.09
-$0.88
-$0.66
-$0.45
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 9, Pre-Market